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Background: Squamous cell carcinoma in situ of the digit presents a complex management problem, which is
usually treated with surgery or radiation or topical agents. The outcome of the surgical treatment can be an
undesirable cosmetic result and loss of function. We report a unique Electronic Brachytherapy technique to treat
the digit, which uses a 50 Kv miniaturized X-ray source with specialized applicators.
Case presentation: A 62-year-old African-American male was presented with a 12-month history of gradual
darkening of the dorsal-distal middle left finger. Examination revealed a hyper pigmented scaly patch on the
proximal to lateral nail fold of the L 3rd finger, nail dystrophy, and vertical split in the lateral section of the nail. The
patient underwent evaluation of the lesion by Plastic Surgery with the removal of the lateral nail and a nail bed
biopsy. Pathology revealed squamous cell carcinoma in situ with a possible focal positive, deep margin. The patient
deliberated over surgical opinions, and eventually decided on radiation. A high dose rate Electronic Brachytherapy
system using the XOFT Accent controller delivered dose of 4000 cGy in eight fractions, twice weekly, with at least
48 hours between fractions and treatment prescribed to a depth of 0 to 2 mm. The Xoft unit has specialized skin
applicators that permit superficial treatment. Parameters assessed included the efficacy, cosmetic results feasibility,
and acute safety of the Electronic Brachytherapy technique.
Conclusions: The patient exhibited moderate redness, hyperpigmentation erythema, desquamation, and Grade 1
to 2 edema acutely (following radiation), which resolved within 1 month of the treatment. Electronic brachytherapy
treatment delivery took about 6 minutes, and the total procedure time was about 15 minutes. At the median
follow-up of one year, the area revealed excellent cosmesis, and there was no infection or fat necrosis,
desquamation, no cancer recurrence, and no evidence of fibrosis at the last follow-up. This suggests that Electronic
Brachytherapy was a viable treatment option for this particular patient.
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Skin cancers are a worldwide health problem. In the
United States, over two million patients are consistently
detected with basal cell or squamous cell carcinoma per
year [1]. Squamous cell carcinoma (SCCA-in-Situ) is a cu-
taneous malignancy, first described by Bowen in the
1900’s. The normal manifestation is an appearance of a
slowly growing, sharply defined erythematous, scaly
plaque. In darker skin types, it can appear as a hyper* Correspondence: arterbery@gmail.com
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distribution, and reproduction in any mediumpigmented, scaly patch or plaque, with the darker skin
type masking the pink color of erythema. It, typically, oc-
curs in the sun exposed areas and in patients over the age
of 60, but any age and location can be affected. Eight per-
cent of untreated cases may, eventually, progress to inva-
sive carcinoma. While surgical removal is, typically, the
standard treatment, other well-defined treatment options
include cryotherapy [2], curettage and electrocautery, sur-
gical excision, laser ablation [3], photodynamic therapy
(PDT), topical 5-FU and topical imiquimod [1,4-7]. Con-
ventional radiation is another treatment option. The treat-
ment options include electron beam or photons given
daily over a series of 3- 6 weeks. The challenge withd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Pre-treatment appearance of the lesion front and side
views. The Patient presented with a pigmented scaly plaque on the
dorsum of the finger and nail bed.
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surface dose to the skin, which can be difficult for the ex-
tremities and require customized bolus. Some authors
have used a water-bath technique, which can improve the
surface dose [8]. Other investigators have used a radio-
active skin patch to deliver a surface dose to the extrem-
ities [9]. High-dose-rate Electronic Brachytherapy has
been used to treat skin cancer with the help of the Lepzig
surface applicators, and has shown effectiveness with an
added advantage of a short radiation treatment using a
condensed hypo fractionated regiment (2 times per week).
The fractionation scheme used for EBT (500 cgy twice a
week for a total dose of 4000 cgy), is identical to that used
with High dose rate after-loaded techniques. Electronic
Brachytherapy technique (EBT) can be used as a treat-
ment for skin malignancy without the use of a radio-
active isotope, but uses a similar hypo fractionated
regimen. It is a form of high-dose-rate Electronic
Brachytherapy but using a miniaturized x-ray tube, in-
stead of a live isotope. Either surgery or radiation
would be a standard treatment approach for squamous
cell carcinoma in Situ of the digit [2-4,8].
In general, the dose ranging from 35 to 65 gray with
standard fractionation is acceptable. Other fractionation
regimens are also acceptable that are not necessarily
daily. Optimal external beam radiation treatment regi-
men, typically, includes fractions that range from 2 to
3.5 centigray. This method ensures greater benefit in
terms of better normal tissues preservation and superior
aesthetic functional outcome [10].
The risk factors that can predispose individuals to
these conditions include prolonged sun exposure,
chronic immunosuppressive, and arsenic exposure [11].
The traditional management of Bowen’s disease is surgi-
cal excision or Mohs surgery [12]. However, when
Bowen’s disease or squamous cell carcinoma occurs in
the digits, surgical removal can lead to scar contracture,
loss of the fingernail, or amputation in extensive cases.
Alternative treatments, such as cryotherapy, photo-
dynamic therapy, and topical creams have other draw-
backs, such as variable response rate, dependence on
patient compliance for topical creams, and variability in
the technique (cryotherapy and PDT8). Others have
tried a combination of photodynamic therapy and radi-
ation [13]. There are some additional limited data that
suggest carbon dioxide laser vaporization for Bowne’s
disease may be effective. All of these nonsurgical and
non-radiation approaches are considered in order to
spare function but have limitations since they have been
only moderately successful [14].
Case presentation
In this case study, the patient was, primarily, treated
with a superficial Electronic Brachytherapy techniqueusing the surface applicators. Customized lead shield
was used to minimize the dose to the unintended areas
(Figures 1, 2, 3, 4).
The 62-year-old African-American male presented the
condition of squamous cell carcinoma in Situ of the
digit. Treatment planning and simulation was performed
using customized mobilization and thermoplastic mold
around the hand and fingers and the patient was lying
supine on the CT simulator couch. This allowed
complete immobilization of the fingers as well as the
hand. CT scans of the extremity were taken to evaluate
the lesion depth for treatment, planning, and the appro-
priate surface areas for the custom applicator. Accept-
able clinical target volume around the tumor was a
3 mm margin due to the sharp fall off of the source.
Then, a customized lead shield (used as a cut out) and a
3.5 cm cone applicator were selected. The half-value layer
of the lead was calculated in order to block the unin-
tended areas and decrease the amount of dose to the un-
involved tissues. After simulation, the depth calculation
was based on the thickness of the lesion, and then, the
treatment was delivered to the patient. The Xoft skin ap-
plicators are calibrated with fixed depth dose curves. For
example if you prescribe to .5 cm from the applicator
Figure 2 Clinical set up of treatment with Xoft machine.
Selected treatment cone is placed directly on the surface of the
finger. The xoft machine and the electronic source are inserted
directly into the hollow cone to allow the dose delivery directly to
the area.
Figure 4 Post-treatment, 6 month, hypopigmentation was seen
in areas of re-pigmentation. The patient has complete and normal
function and good cosmesis.
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sive calibration processes ensured correct dose output of
these applicators prior to each treatment. Primary obser-
vations revealed the average normal dose-rate output of
the skin surface for the 35 mm applicator was 1.35 grayFigure 3 Customized lead cut out used on the digit to protect
uninvolved areas. The half-value of lead is calculated to shield
100% of non-involved tissues. The cut out is designed based on the
clinical shape and size of the lesion with a small margin.per minute with a positive/negative 5% variation. The out-
put variation is within 2%. Calculations of the effective
source-surface distance were carried out on the air-gap
measurements for all applicator sizes, and the field flatness
and symmetry were well within 5%. Calibration in this
case study was identical to cases reported elsewhere on
quality assurance for this technique [15].
Clinically, the patient had a fair amount of keratotic epi-
thelialization, and thus, the initial treatment prescription
was to 2 mm in depth. After the first three fractions, the
patient developed severe irritation and the lesion appeared
to flatten, and thus, the doses for the remaining fractions
delivered at the skin-surface. The patient received a total
dose of 4000 centigray delivered in 500 centigray fractions
over eight fractions twice a week with 48 hours between
fractions. The total time for radiation delivery was about
5 minutes, and the total mean procedure time was about
15 minutes from the start to finish (including the clinical
set up). The patient tolerated the treatment well and had
no recurrence of the cancer in the one-year follow-up and
overall cosmesis was excellent in the patient. There was
no infection, fat necrosis, desquamation, or cancer recur-
rences. There was no evidence of fibrosis, at the last
follow-up session. There has been no recurrence of tumor.
At the site of the radiation application, mild skin des-
quamation developed in the weeks following the treat-
ment. This reaction healed with minimal fibrosis and
epithelialized quickly. There was no adverse reaction to
the radiation, except for the appearance of a small 2 mm
area of moist desquamation, appropriately one week after
the last treatment, which resolved with topical agents. The
patient also experienced hypopigmentation that is slowly
resolving.
Discussion
Ever since its introduction in 2009, the Xoft Accent
Electronic Brachytherapy unit with skin applicators has
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tube generates 50 kV photon radiations, which requires
minimal shielding. The cone-shaped skin applicators
come in a variety of sizes from 5 mm – 50 mm, which
allows precise placement of the radiation directly to the
lesion. The patient can be treated in any position, and in
almost any location with minimal shielding. Electronic
Brachytherapy is a unique cancer treatment modality,
which is an alternative for the treatment of the digit,
when compared with external beam radiation therapy,
chemotherapy and topical agents. One of the advantages
of Electronic Brachytherapy is that the treatment is rela-
tively sophisticated, much localized, non-invasive, and
allows superficial delivery of radiation in a variety of set-
tings. Because of the twice-a-week treatment and only a
total of 8 fractions, this technique has a higher degree of
patient acceptance and compliance. It may be suitable
for lesions in an unusual location, the elderly, and in
cases when patients are unable to tolerate five weeks of
daily treatment. The significant advantage is patient con-
venience and the lack of regulatory issue associated with
an after-loaded source. This technique requires less
physicist supervision and the machine can be operated
by the therapists, increasing treatment efficiency. There
is limited data about the long term effectiveness of this
technique and the largest experience has short follow up
and excellent tumor control similar to what is seen with
external beam therapy (16) Although, we did see acute
forms of skin reaction, such as erythema, dry desquam-
ation, and mild moist desquamation, these conditions
healed quickly with minimal toxicity, and are due to the
high surface dose in this technique. Hyperpigmentation
or hypopigmentation of radiated skin may develop as
chronic reaction within a couple of months after com-
pletion of the treatment, but this reaction will fade. It
may also progress to a vitiligo appearance in some pa-
tients [16].
Conclusion
Superficial skin tumors of the digit are a challenging man-
agement problem, and can be effectively treated by Elec-
tronic Brachytherapy (EBT) using the superficial skin
applicators. EBT to the skin, for squamous cell carcinoma
in situ, is a feasible alternative to surgery for squamous
cell carcinoma of the digit. Further exploration and more
extensive follow-up on this method will help to gain better
insights and shed light in the direction of clinical useful-
ness of the procedure. This case study positively indicates
that Electronic Brachytherapy using superficial skin appli-
cators is a local therapeutic solution for the treatment of
this case. It is a convenient option and a non-invasive
therapy with satisfactory cosmetic results and outcome for
this patient. The convenience and portability of this tech-
nique can allow more patients access to care.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal and can be
sent by fax or electronically for review.
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